Citadel Advisors
RNTX

Citadel Advisors’s Rein Therapeutics RNTX Stock Holding History

Citadel Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.54M Buy
+2,438,711
New +$2.95M ﹤0.01% 6035
2026
Q1 		– Sell
-120,083
Closed -$139K – 14626
2025
Q4 		$139K Buy
120,083
+91,882
+326% +$127K ﹤0.01% 11383
2025
Q3 		$32.3K Sell
28,201
-19,793
-41% -$25.1K ﹤0.01% 12380
2025
Q2 		$67.2K Buy
+47,994
New +$86.4K ﹤0.01% 11619
2024
Q2 		– Sell
-13,810
Closed -$89.8K – 15641
2024
Q1 		$89.8K Buy
+13,810
New +$66.1K ﹤0.01% 11502
2021
Q3 		– Sell
-1,511
Closed -$38K – 14824
2021
Q2 		$38K Sell
1,511
-831
-35% -$20.7K ﹤0.01% 13434
2021
Q1 		$67K Buy
+2,342
New +$80.3K ﹤0.01% 12764
2020
Q4 		– Sell
-2,153
Closed -$56K – 11638
2020
Q3 		$56K Buy
+2,153
New +$50.7K ﹤0.01% 9563
2019
Q4 		– Sell
-628
Closed -$8K – 9887
2019
Q3 		$8K Buy
+628
New +$8.69K ﹤0.01% 9055
2019
Q2 		– Sell
-713
Closed -$28K – 9984
2019
Q1 		$28K Sell
713
-313
-31% -$9.75K ﹤0.01% 9011
2018
Q4 		$17K Buy
+1,026
New +$41.2K ﹤0.01% 8807
2017
Q3 		– Sell
-634
Closed -$141K – 8149
2017
Q2 		$141K Buy
+634
New +$139K ﹤0.01% 6783

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Citadel Advisors's RNTX Position: Q2 2026 in Review

Citadel Advisors opened a new position in Rein Therapeutics (RNTX) in Q2 2026: 2,438,711 shares worth $2.54M. The stake represents ﹤0.01% of the portfolio and ranks #6035 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in RNTX as recently as Q4 2025.

Citadel Advisors first reported a position in RNTX in Q2 2017 and has held it in 12 quarters since. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Citadel Advisors held 2,438,711 shares of Rein Therapeutics worth $2.54M as of Q2 2026.
  • Rein Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Rein Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6035 holding.
  • Citadel Advisors first reported a position in Rein Therapeutics in Q2 2017 and has held it in 12 quarters since.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.